Trial · NCT04819568
Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
NCT04819568, Not applicable, Unknown, Institute of Liver and Biliary Sciences, India
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock. Trials, record NCT04819568. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04819568
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
- NCT number
- NCT04819568
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 310 participants, estimated
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Conditions
- Liver Cirrhosis
- Interventions
- Terlipressin, Standard of Care
- First posted
- 2021-03-29
- Last updated
- 2021-11-10
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reversal of shock | 72 hours | DISCONTINUATION OF NOREPINEPHRINE IS CONSIDERED AS REVERSAL OF SHOCK. |
| Secondary | Time to reversal of shock | 1 Year | |
| Secondary | Incidence of adverse effects and discontinuation of therapy due to adverse effects | 24 hours | |
| Secondary | Incidence of adverse effects and discontinuation of therapy due to adverse effects | Day 3 | |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | 24 hours | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | Day 3 | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | Day 7 | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Mortality | 28 days | |
| Secondary | Improvement in SOFA score | 24 hours | IMPROVEMENT BY ATLEAST 2 POINTS |
| Secondary | Improvement in SOFA score | Day 3 | IMPROVEMENT BY ATLEAST 2 POINTS |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04819568
GET https://conductscience.org/api/trials/v1/NCT04819568/registered